Explore the words cloud of the GLYCANC project. It provides you a very rough idea of what is the project "GLYCANC" about.
The following table provides information about the project.
WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER
|Coordinator Country||Germany [DE]|
|Total cost||567˙000 €|
|EC max contribution||567˙000 € (100%)|
1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
|Duration (year-month-day)||from 2015-07-01 to 2019-06-30|
Take a look of project's partnership.
|1||WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER||DE (MUENSTER)||coordinator||103˙500.00|
|2||UNIVERSITA DEGLI STUDI DELL'INSUBRIA||IT (VARESE)||participant||126˙000.00|
|3||PANEPISTIMIO PATRON||EL (RIO PATRAS)||participant||103˙500.00|
|4||SEMMELWEIS EGYETEM||HU (BUDAPEST)||participant||67˙500.00|
|5||"NATIONAL CENTER FOR SCIENTIFIC RESEARCH ""DEMOKRITOS"""||EL (AGIA PARASKEVI)||participant||45˙000.00|
|6||UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE||FR (REIMS)||participant||45˙000.00|
|7||UPPSALA UNIVERSITET||SE (UPPSALA)||participant||45˙000.00|
|8||FIDIA FARMACEUTICI SPA||IT (Abano Terme)||participant||27˙000.00|
|9||SEREND-IP GMBH||DE (MUENSTER)||participant||4˙500.00|
|10||CAIRO UNIVERSITY||EG (GIZA)||partner||0.00|
|11||CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET)||AR (BUENOS AIRES)||partner||0.00|
|12||EWHA WOMANS UNIVERSITY||KR (Seoul)||partner||0.00|
|13||UNIVERSIDADE FEDERAL DO RIO DE JANEIRO||BR (RIO DE JANEIRO)||partner||0.00|
Cancer is a leading cause of mortality within the aging European population. Therapeutic targeting is hampered by the complexity of the disease, which includes not only molecular changes within the tumor cell itself, but also within its microenvironment. Tumor angiogenesis, tumor-stroma interactions, interactions with immune cells, with the extracellular matrix and cancer stem cell niches allow for malignant cell survival and promote metastasis, the leading cause for cancer-associated mortality. Proteoglycans (PGs) and glycosaminoglycans (GAGs) – structurally diverse carbohydrates of the extracellular matrix and cell surfaces - have emerged as novel biomarkers and molecular players both within tumor cells and their microenvironment, as they integrate signals from growth factors, chemokines and integrins, and cell-cell as well as matrix adhesion. Importantly, their expression is dysregulated in numerous tumor entities, and has been shown to modulate each of the hallmarks of cancer as defined by Hanahan and Weinberg (Cell 2011). We hypothesize that dysregulated function of PGs and GAGs simultaneously affects all molecular steps towards cancer metastasis as a general principle applicable to multiple tumor entities. Pharmacological modulation of their function thus emerges as an attractive multitargeted antitumoral approach which simultaneously acts at multiple levels of disease progression. Besides providing extensive knowledge transfer and training for researchers, the combined expertise of the GLYCANC consortium aims at performing a detailed structural analysis of PG and GAG glycans in disease using state-of-the art methodology, analysing their regulation via epigenetic mechanisms and microRNAs, and elucidating molecular mechanisms underlying aberrant PG and GAG function. GLYCANC will lead to a deeper understanding of glycan structures and glycan-dependent mechanisms promoting cancer progression, providing the basis for rational multitargeted anticancer approaches.
Work performed, outcomes and results: advancements report(s)
|Chemotherapeutic resistance||Documents, reports||2020-01-28 11:49:34|
|In vitro analysis of microRNA-dependent Syndecan-1 regulation in IBC||Documents, reports||2020-01-28 11:49:34|
|Mechanistic in vitro investigation of Syndecan-dependenttranscriptional activation||Documents, reports||2020-01-28 11:49:34|
|Inhibitory effect of 4- MU in vivo||Documents, reports||2020-01-28 11:49:34|
|Analysis of signaling pathways||Documents, reports||2020-01-28 11:49:34|
|Methods for preprocessing and processing of spectral data||Documents, reports||2020-01-28 11:49:34|
|In vitro functional assays in a novel 3D culture system||Documents, reports||2020-01-28 11:49:33|
|Functional in vitro studies||Documents, reports||2020-01-28 11:49:33|
|In vivo study on the premetastatic niche||Documents, reports||2020-01-28 11:49:33|
|Immune cells in the microenvironment||Documents, reports||2020-01-28 11:49:33|
|Angiogenesis regulators||Documents, reports||2020-01-28 11:49:33|
|Nanostic analysis||Documents, reports||2020-01-28 11:49:33|
|Role of Syndecan-1 oligomerization in FAK activation||Documents, reports||2020-01-28 11:49:33|
|Proof of concept for in vivo Raman probes for diagnosis of melanoma in patients and application to tumor-associated macrophages||Documents, reports||2020-01-28 11:49:34|
|Analysis of angiogenic factors in immunomodulatory cells||Documents, reports||2020-01-28 11:49:33|
|3D culture||Documents, reports||2020-01-28 11:49:33|
|Functional impact of miRNA-dependent PG and HAS regulation||Documents, reports||2020-01-28 11:49:33|
|Microvascular density||Documents, reports||2020-01-28 11:49:33|
|Role of PGs in TGFbeta induced EMT||Documents, reports||2020-01-28 11:49:33|
|Therapeutic potential of Ascidian GAGs||Documents, reports||2020-01-28 11:49:33|
|Characterization of HA molecular weight from tumor and control tissue of at least three in vivo mouse tumor models||Documents, reports||2020-01-28 11:49:33|
|ChIP experiments||Documents, reports||2020-01-28 11:49:33|
|Impact of conventional therapeutics on the premetastatic niche||Documents, reports||2020-01-28 11:49:31|
|microRNA-regulation of Syndecan-1 in clinical IBC specimens||Documents, reports||2020-01-28 11:49:29|
|In vitro study of the premetastatic niche||Documents, reports||2020-01-28 11:49:31|
|Changes in EMT marker expression||Documents, reports||2020-01-28 11:49:31|
|Impact of PGs and GAGs on premature senescence of cancer cells||Documents, reports||2020-01-28 11:49:30|
|Characterization of HS disaccharide structure from 8 breast cancer cell lines with altered Syndecan-1, 3-O-HS sulfation and 2-O-HS sulfation||Documents, reports||2020-01-28 11:49:29|
|Epigenetic HAS2 promoter regulation||Documents, reports||2020-01-28 11:49:30|
|Workshop on epigenetic regulation||Websites, patent fillings, videos etc.||2020-01-28 11:49:30|
|Workshop on PGs and GAGs in metastasis||Websites, patent fillings, videos etc.||2020-01-28 11:49:31|
|Diagnostic value of Syndecan-1 in IBC||Documents, reports||2020-01-28 11:49:31|
|In vivo model of hepatocarcinogenesis||Documents, reports||2020-01-28 11:49:29|
|microRNA regulation of Glypican-1, Syndecan-2 and HAS1-3 in breast and colon cancer||Documents, reports||2020-01-28 11:49:29|
|Flow cytometric analysis of SP and ALDH phenotype||Documents, reports||2020-01-28 11:49:30|
|Standardized Protocol for Tissue Microarray Analysis by FTIR and RAMAN spectroscopy||Documents, reports||2020-01-28 11:49:32|
|Evaluation of HA related enzyme expression||Documents, reports||2020-01-28 11:49:31|
|Standardized protocol for FTIR and RAMAN spectroscopic analysis of GAGs in cells and conditioned media.||Documents, reports||2020-01-28 11:49:30|
|Impact of PG/HA on DNA damage response||Documents, reports||2020-01-28 11:49:30|
|qPCR analysis of angiogenic factors in tumors||Documents, reports||2020-01-28 11:49:31|
|Flow cytometric and qPCR analysis of stem cell markers||Documents, reports||2020-01-28 11:49:32|
|Correlation of GAG structure with clinicopathological parameters||Documents, reports||2020-01-28 11:49:31|
|Proof of concept to determine GAGs composition in cancer stromal tissue||Documents, reports||2020-01-28 11:49:32|
|Spectroscopic delineation of the expression of GAGs in mice lung metastatic nodules||Documents, reports||2020-01-28 11:49:32|
|Establichment of GLYCANC Website||Websites, patent fillings, videos etc.||2020-01-28 11:49:31|
|Spectroscopic delineation of the expression of GAGs in murine melanoma, and PG-manuipulated cancer cell lines||Documents, reports||2020-01-28 11:49:31|
|Changes in invasive behaviour||Documents, reports||2020-01-28 11:49:31|
|Analysis of glioblastoma cell line GAG structure||Documents, reports||2020-01-28 11:49:31|
Take a look to the deliverables list in detail: detailed list of GLYCANC deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLYCANC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "GLYCANC" are provided by the European Opendata Portal: CORDIS opendata.